Pharma Focus Asia
KP - Choose our fully recyclable blister films

New Patritumab Deruxtecan (HER3-DXd) Discovered for the Treatment of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo discovered new patritumab deruxtecan to treat patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC).

Patritumab deruxtecan (HER3-DXd), is the firt irst-in-class HER3 directed antibody drug conjugate (ADC), applicable with third-generation tyrosine kinase inhibitor (TKI) and platinum-based therapies on or after treatment.

Patritumab deruxtecan the new treatment improves the patients surving with TKI-resistant, EGFR-mutated non-small cell lung cancer, and therby overcomes resistance.

Patritumab deruxtecan (HER3-DXd) is a monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker. It is being evaluated in a comprehensive development program among various cancers both as monotherapy and in combination with other anticancer treatments. Moreover, patritumab deruxtecan an investigational medicine is not approved in any country for medical use.

Lung cancer one of the most common type of cancer increases the world’s mortality rates to 80 to 85 percent consisting of NSCLC. In 2020, it is estimated that new lung cancer cases raised to 2.2 million and 1.8 million deaths. In among 50 percent of patients though NSCLC is diagnosed at an advanced stage have resulted in poor outcomes after  each line of subsequent therapy.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024